Several Phase III prospective clinical trials are ongoing to explore the efficacy and safety of the combination of immunotherapy with chemotherapy and/or antiangiogenic therapy in EGFR-mutant NSCLC progressed on EGFR-TKIs, including KEYNOTE-789, KEYNOTE-722, ORIENT-31, and JS001 study (NCT03924050). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.